Metastatic Malignant Neoplasm in the Brain clinical trials
71 active trials name this condition. Describe your situation to see which ones you may be eligible for.
Refine by biomarker
By location
- Stereotactic Radiosurgery Dose Escalation for Brain Metastases
- Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
- Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
- Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
- Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
- Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
- A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases
- REMASTer: REcurrent Brain Metastases After SRS Trial
- UCSD Image-Guided Cognitive-Sparing Radiosurgery for Brain Metastases
- Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors
- A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
- Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
- Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
- NTS-WBRT in Brain Metastases
- Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
- Phase I Study of Fractionated Stereotactic Radiation Therapy
- Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases
- Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)
- Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
- Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
- EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
- Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
- Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
- Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery
- Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
- 18F-FLUC PET/MR in Patients With Brain Mets
- Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
- Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
- 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery
- Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
- Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
- Evaluation of the CONVIVO System
- Development of MRF for Characterization of Brain Tumors After Radiotherapy
- Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Metastatic Malignant Neoplasm in the Brain” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.